Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 55Neoplasms 15Sarcoma 12Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Ovarian Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Liposarcoma 2Leiomyosarcoma 2Carcinoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Lymphoma 1

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × eribulin × Clear all
NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡